The FDA has approved Datroway (datopotamab deruxtecan) to treat adults with unresectable or metastatic, HR+, HER2- breast cancer who have received prior endocrine therapy and chemotherapy.

You should change the pads every 48 hours, and note that they do not work on moles, birthmarks, warts with hair growing from ...